Terzah M Horton

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study
    Terzah M Horton
    University of Texas Health Science Center, San Antonio, TX, USA
    Clin Cancer Res 11:1884-9. 2005
  2. ncbi Educational paper. The development of new therapies for pediatric oncology
    Terzah M Horton
    Texas Children s Cancer Center, Baylor College of Medicine, 1102 Bates, Suit 750, Houston, TX 77030, USA
    Eur J Pediatr 170:555-9. 2011
  3. ncbi Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 54:872-8. 2010
  4. ncbi Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Cancer Ther 8:2232-42. 2009
  5. ncbi Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 25:4922-8. 2007
  6. ncbi A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, Texas, USA
    Pediatr Blood Cancer 50:788-92. 2008
  7. ncbi A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study
    Terzah M Horton
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 13:1516-22. 2007
  8. ncbi Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, 6621 Fannin, MC 3 3320, Houston, 77030, USA
    Cancer Chemother Pharmacol 58:13-23. 2006
  9. ncbi A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)
    Jodi A Muscal
    Texas Children s Cancer Center and Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 60:390-5. 2013
  10. ncbi Development and validation of a fluorogenic assay to measure separase enzyme activity
    Dipanjan Basu
    Department of Pediatric Hematology Oncology, Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    Anal Biochem 392:133-8. 2009

Research Grants

  1. Proteosome Inhibition Therapy for Hematologic Malignancy
    Terzah Horton; Fiscal Year: 2007

Detail Information

Publications11

  1. ncbi Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study
    Terzah M Horton
    University of Texas Health Science Center, San Antonio, TX, USA
    Clin Cancer Res 11:1884-9. 2005
    ..To evaluate the toxicity, antileukemic activity, and pharmacology of raltitrexed administered weekly for 3 weeks to patients with refractory or recurrent leukemia...
  2. ncbi Educational paper. The development of new therapies for pediatric oncology
    Terzah M Horton
    Texas Children s Cancer Center, Baylor College of Medicine, 1102 Bates, Suit 750, Houston, TX 77030, USA
    Eur J Pediatr 170:555-9. 2011
    ....
  3. ncbi Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an international consensus conference
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 54:872-8. 2010
    ..This functional DLT definition is being tested in two Children's Oncology Group (COG) ALL clinical trials...
  4. ncbi Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Cancer Ther 8:2232-42. 2009
    ..In conclusion, although ABT-888 potentiation of TMZ was most pronounced in MMR-deficient cells with low MGMT activity, neither MMR proficiency nor MGMT overexpression completely abrogated ABT-888 potentiation of TMZ...
  5. ncbi Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 25:4922-8. 2007
    ..To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia...
  6. ncbi A Phase 1 and pharmacokinetic clinical trial of paclitaxel for the treatment of refractory leukemia in children: a Children's Oncology Group study
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, Texas, USA
    Pediatr Blood Cancer 50:788-92. 2008
    ....
  7. ncbi A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study
    Terzah M Horton
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 13:1516-22. 2007
    ..A phase 1 study to determine the maximum-tolerated dose, dose-limiting toxicity, pharmacokinetics, and biological effects of bortezomib in children with recurrent/refractory leukemia...
  8. ncbi Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, 6621 Fannin, MC 3 3320, Houston, 77030, USA
    Cancer Chemother Pharmacol 58:13-23. 2006
    ..These data suggest bortezomib could potentiate the cytotoxic effects of combination chemotherapy in patients with leukemia...
  9. ncbi A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916)
    Jodi A Muscal
    Texas Children s Cancer Center and Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 60:390-5. 2013
    ..A pediatric Phase I trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities (DLTs), and pharmacokinetics (PK) of vorinostat and bortezomib, in patients with solid tumors...
  10. ncbi Development and validation of a fluorogenic assay to measure separase enzyme activity
    Dipanjan Basu
    Department of Pediatric Hematology Oncology, Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    Anal Biochem 392:133-8. 2009
    ..We used this assay to quantify separase activity during cell cycle progression and in a panel of human tumor cell lines as well as leukemia patient samples...
  11. ncbi Diverse pathways mediate chemotherapy-induced cell death in acute lymphoblastic leukemia cell lines
    Dong-Joon Min
    Division of Pediatric Hematology/Oncology, The Stephen D. Hassenfeld Children's Center for Cancer and Blood Diseases, New York University Cancer Institute, 317 East 34th Street, New York, NY 10016, USA
    Apoptosis 11:1977-86. 2006
    ..This study further documents the highly variable nature of cell death programs in ALL and provides the foundation for cell death pathway modulation to improve ALL cure rates without increasing chemotherapy-related toxicity...

Research Grants2

  1. Proteosome Inhibition Therapy for Hematologic Malignancy
    Terzah Horton; Fiscal Year: 2007
    ..The phase I studies will be used to further refine correlative biology studies for the proposed phase 2 clinical trials that will examine the effectiveness of bortezomib as a chemosensitizing agent in relapsed ALL and HL. ..